Table 2.

Varimax rotated factor pattern: randomization window (all subjects) n = 990

	Factor
	Lung Function	Ratio/BD response	Inflammatory/Atopy	Symptoms	Exacerbations
Pre-BD FEV1	0.979	0.161	0.024	−0.044	−0.056
Pre-BD FVC	0.975	−0.188	0.067	−0.005	−0.054
Pre-BD Peak Flow	0.750	0.120	0.123	−0.057	−0.030
Pre-BD FEV1/FVC ratio	−0.085	0.942	−0.133	−0.106	0.012
FEV1 BD Responsiveness	−0.178	−0.644	0.240	0.157	0.023
Serum IgE level (ng/ml)*	0.100	−0.078	0.692	0.049	−0.037
No. of positive core skin tests	0.132	−0.017	0.583	0.109	−0.002
Total Eosinophil Count (mm3)*	0.007	−0.122	0.520	0.003	0.027
FEV1 PC20 methacholine, mg/ml*	0.109	0.292	−0.428	−0.193	−0.066
Mean Symptom Score	0.055	−0.082	0.093	0.708	0.179
No. of days with albuterol puffs	−0.050	−0.077	0.078	0.502	0.247
No. of episode-free days	0.081	0.096	−0.066	−0.661	0.110
No. of doctor contacts	−0.014	0.013	0.020	0.085	0.571
No. of school absences	−0.037	0.021	−0.072	−0.025	0.541
No. of nights awakened	−0.034	−0.067	0.095	0.218	0.359
No. of days with any prednisone use**	NA	NA	NA	NA	NA
% Variance Explained†	17.1%	10.1%	9.3%	8.9%	5.8%

^*Data was logarithimically transformed for factor analysis

^**Participants were taken off of Prednisone during the 28 day screening period but could use it afterwards

^†Common variance explained by all 5 factors: 58.9%